Noribogainalog

Last updated

Noribogainalog
Noribogainalog.svg
Noribogainalog 3D.png
Clinical data
Other namesNor-IBG; 9-Hydroxyibogaminalog; GATC-021; GATC021
Drug class Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • 3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indol-9-ol
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C13H16N2O
Molar mass 216.284 g·mol−1
3D model (JSmol)
  • CN1CCC2=C(CC1)NC3=C2C=C(C=C3)O
  • InChI=1S/C13H16N2O/c1-15-6-4-10-11-8-9(16)2-3-12(11)14-13(10)5-7-15/h2-3,8,14,16H,4-7H2,1H3
  • Key:OOROJSRWMMKEQK-UHFFFAOYSA-N

Noribogainalog (nor-IBG), also known as 9-hydroxyibogaminalog or as GATC-021, is a drug of the ibogalog family related to noribogaine. [1] [2] [3] It is a simplified analogue of noribogaine. [1] [2]

Contents

Pharmacology

Pharmacodynamics

Noribogainalog acts as a potent serotonin 5-HT2A receptor partial agonist (EC50 Tooltip half-maximal effective concentration ≈ 90 nM; Emax Tooltip maximal efficacy = 35–45%). [2] [3] It is also a partial agonist of the serotonin 5-HT6 receptor (Emax = 29%), whereas it is not an agonist of the serotonin 5-HT2B and 5-HT7 receptors. [3] The drug additionally has activity as a dopamine transporter (DAT) chaperone. [4]

Noribogainalog does not affect locomotor activity, does not produce the head-twitch response, and does not affect various other physiological and behavioral measures. [2] However, it does produce analgesic effects that can be diminished by the serotonin 5-HT2A receptor antagonist ketanserin. [2] In addition, a subsequent study found that the highest assessed dose produced significant hypolocomotion and that the drug also reduced fentanyl self-administration. [3]

Pharmacokinetics

Noribogainalog shows relatively low expected blood–brain barrier permeability. [2]

Chemistry

Synthesis

The chemical synthesis of noribogainalog has been described. [3]

Analogues

Analogues of noribogainalog include catharanthalog, ibogainalog, ibogaminalog, PNU-22394, tabernanthalog, and noribogaine, among others.

History

Noribogainalog was first described in the scientific literature by David E. Olson and colleagues by 2021. [1]

See also

References

  1. 1 2 3 Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. (January 2021). "A non-hallucinogenic psychedelic analogue with therapeutic potential". Nature. 589 (7842): 474–479. Bibcode:2021Natur.589..474C. doi:10.1038/s41586-020-3008-z. PMC   7874389 . PMID   33299186.
  2. 1 2 3 4 5 6 Arias HR, Micheli L, Jensen AA, Galant S, Vandermoere F, Venturi D, et al. (March 2025). "Ibogalogs decrease neuropathic pain in mice through a mechanism involving crosstalk between 5-HT2A and mGlu2 receptors". Biomedicine & Pharmacotherapy. 184 117887. doi:10.1016/j.biopha.2025.117887. hdl: 2158/1423286 . PMID   39938347.
  3. 1 2 3 4 5 Lallai V, Kho S, Martin AC, Fowler JP, Roach ML, Wang K, et al. (April 2026). "AI-derived therapeutic development of a serotonin receptor-targeting drug for the treatment of opioid use disorder". Proc Natl Acad Sci U S A. 123 (15): e2516807123. doi:10.1073/pnas.2516807123. PMID   41941629.{{cite journal}}: CS1 maint: article number as page number (link)
  4. ↑ Sutton C, Williams EQ, Homsi H, Beerepoot P, Nazari R, Han D, et al. (2022). "Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones". Frontiers in Cellular Neuroscience. 16 832536. doi: 10.3389/fncel.2022.832536 . PMC   9124866 . PMID   35614973.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.